Irradiation of Human Prostate Cancer Cells Increases Uptake of Antisense Oligodeoxynucleotide
Creators
- 1. Division of Urology, University of Florida, Jacksonville, FL (United States)
- 2. Prostate Cancer Translational Working Group, University of Florida, Jacksonville, FL (United States)
- 3. Genta Incorporated, Berkeley Heights, NJ (United States)
- 4. Department of Surgery, University of Florida, Jacksonville, FL (United States)
- 5. Department of Urology, Nara Medical School, Nara (Japan)
- 6. Prostate Cancer Translational Working Group, University of Florida, Jacksonville, FL (United States) and Division of Urology, University of Florida, Jacksonville, FL (United States)
Description
Purpose: To investigate whether irradiation before antisense Bcl-2 oligodeoxynucleotide (ODN) administration enhances tissue uptake, and whether periodic dosing enhances cellular uptake of fluorescently labeled ODN relative to constant dosing. Methods and Materials: PC-3-Bcl-2 cells (prostate cancer cell line engineered to overexpress Bcl-2) were subjected to increasing doses of irradiation (0-10 Gy) with or without increasing concentrations of fluorescently labeled antisense Bcl-2 ODN (G4243). The fluorescent signal intensity was quantified as the total grain area with commercial software. In addition, PC-3-Bcl-2 subcutaneous xenograft tumors were treated with or without irradiation in combination with various dosing schemas of G4243. The uptake of fluorescent G4243 in tumors was quantitated. Results: The uptake of G4243 was increased in prostate cancer cells exposed to low doses of irradiation both in vitro and in vivo. Irradiation before G4243 treatment resulted in increased fluorescent signal intensity in xenograft tumors compared with those irradiated after G4243 treatment. A single weekly dose of G4243 produced higher G4243 uptake in xenograft tumors than daily dosing, even when the total dose administered per week was held constant. Conclusions: These findings suggest that ionizing radiation increases the uptake of therapeutic ODN in target tissues and, thus, has potential to increase the efficacy of ODN in clinical applications
Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2007.03.058;
- PII
- S0360-3016(07)00648-7;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 68
- Journal Issue
- 4
- Journal Page Range
- p. 1161-1168
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 38104847
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- CARCINOMAS; COMPUTER CODES; IN VITRO; IN VIVO; IONIZING RADIATIONS; IRRADIATION; PROSTATE; RADIATION DOSES; UPTAKE
- Descriptors DEC
- BODY; DISEASES; DOSES; GLANDS; MALE GENITALS; NEOPLASMS; ORGANS; RADIATIONS
Optional Information
- Copyright
- Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved.